The promising results observed by Ganesh et al., where combination therapy with CTLA-4 and PD -1 antibodies led to complete remission in the majority of mice with Wnt-driven tumours, further underscore the therapeutic potential of targeting this pathway in ACC (58). This evidence concerns the gene RPL17 and neoplasm.